In 2017, the Food and Drug Administration (FDA) approved a medication for gene therapy in patients with autosomal recessive retinitis pigmentosa caused by biallelic pathogenic variants in the RPE65 gene. The gene discussed is RPE65; the disease is autosomal recessive retinitis pigmentosa.